AU2014213009B2 - Anti-CD83 antibodies and use thereof - Google Patents

Anti-CD83 antibodies and use thereof Download PDF

Info

Publication number
AU2014213009B2
AU2014213009B2 AU2014213009A AU2014213009A AU2014213009B2 AU 2014213009 B2 AU2014213009 B2 AU 2014213009B2 AU 2014213009 A AU2014213009 A AU 2014213009A AU 2014213009 A AU2014213009 A AU 2014213009A AU 2014213009 B2 AU2014213009 B2 AU 2014213009B2
Authority
AU
Australia
Prior art keywords
seq
binding protein
sequence
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014213009A
Other languages
English (en)
Other versions
AU2014213009A1 (en
Inventor
Derek Nigel John Hart
Martina Louise Jones
Stephen Michael Mahler
James D. Marks
Trent Phillip Munro
David John MUNSTER
Therese Ann SELDON
Eunice Yu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kira Biotech Pty Ltd
University of Queensland UQ
University of California San Diego UCSD
Original Assignee
Kira Biotech Pty Ltd
University of Queensland UQ
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kira Biotech Pty Ltd, University of Queensland UQ, University of California Berkeley, University of California San Diego UCSD filed Critical Kira Biotech Pty Ltd
Publication of AU2014213009A1 publication Critical patent/AU2014213009A1/en
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, DENDROCYTE BIOTECH PTY LTD reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Request for Assignment Assignors: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, TRANSBIO LTD
Application granted granted Critical
Publication of AU2014213009B2 publication Critical patent/AU2014213009B2/en
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND, Kira Biotech Pty Limited reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Request for Assignment Assignors: DENDROCYTE BIOTECH PTY LTD, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNIVERSITY OF QUEENSLAND
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014213009A 2013-02-01 2014-01-31 Anti-CD83 antibodies and use thereof Ceased AU2014213009B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759780P 2013-02-01 2013-02-01
US61/759,780 2013-02-01
PCT/AU2014/000066 WO2014117220A1 (en) 2013-02-01 2014-01-31 Anti-cd83 antibodies and use thereof

Publications (2)

Publication Number Publication Date
AU2014213009A1 AU2014213009A1 (en) 2015-09-17
AU2014213009B2 true AU2014213009B2 (en) 2019-01-03

Family

ID=51261317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014213009A Ceased AU2014213009B2 (en) 2013-02-01 2014-01-31 Anti-CD83 antibodies and use thereof

Country Status (13)

Country Link
US (3) US9840559B2 (https=)
EP (2) EP3626743A1 (https=)
JP (2) JP6539585B2 (https=)
KR (2) KR102204127B1 (https=)
CN (1) CN105531289B (https=)
AU (1) AU2014213009B2 (https=)
CA (1) CA2899960C (https=)
DK (1) DK2951208T3 (https=)
ES (1) ES2762622T3 (https=)
MX (1) MX2015010023A (https=)
NZ (1) NZ711543A (https=)
PT (1) PT2951208T (https=)
WO (1) WO2014117220A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
WO2016061617A1 (en) * 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3681536A4 (en) * 2017-09-13 2021-06-09 Kira Biotech Pty Limited TREATMENT METHOD
KR20200130324A (ko) 2018-02-23 2020-11-18 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Cd83-결합 키메라 항원 수용체
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
JP7701908B2 (ja) * 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
WO2022191550A1 (ko) * 2021-03-09 2022-09-15 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
CN117547553A (zh) * 2023-11-21 2024-02-13 中国人民解放军陆军特色医学中心 Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190051A1 (en) * 2001-11-09 2007-08-16 Abgenix, Inc. Antibodies to CD40
US20110195027A1 (en) * 2008-06-25 2011-08-11 Young Woo Park Cd9-specific human antibodies
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE82588T1 (de) 1986-04-28 1992-12-15 Endotronics Inc Zuchtverfahren fuer leukocyten.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
SG41929A1 (en) 1992-09-25 1997-08-15 Commw Scient Ind Res Org Target binding polypeptide
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042430A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
AU781547B2 (en) * 1999-04-14 2005-05-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2005519586A (ja) * 2001-11-21 2005-07-07 セルテック アール アンド ディー， インコーポレイテッド Ｃｄ８３遺伝子産物を利用したサイトカイン・レベルの操作法
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004048552A2 (en) * 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
JP2006507510A (ja) 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US20090247455A1 (en) 2005-03-31 2009-10-01 Mark Fear Isolation of Inhibitors of IRES-Mediated Translation
CN101155914B (zh) * 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3681536A4 (en) 2017-09-13 2021-06-09 Kira Biotech Pty Limited TREATMENT METHOD

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190051A1 (en) * 2001-11-09 2007-08-16 Abgenix, Inc. Antibodies to CD40
US20110195027A1 (en) * 2008-06-25 2011-08-11 Young Woo Park Cd9-specific human antibodies
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gcnbank Accession No. ACF37389. 31 March 2009 *
Genbank Accession No. ABI35683, 30 December 2007 *

Also Published As

Publication number Publication date
DK2951208T3 (da) 2020-01-13
US20150376277A1 (en) 2015-12-31
ES2762622T3 (es) 2020-05-25
EP3626743A1 (en) 2020-03-25
US9840559B2 (en) 2017-12-12
PT2951208T (pt) 2019-12-30
US11725054B2 (en) 2023-08-15
US10781255B2 (en) 2020-09-22
KR20200120967A (ko) 2020-10-22
KR102449868B1 (ko) 2022-10-04
AU2014213009A1 (en) 2015-09-17
US20200339684A1 (en) 2020-10-29
EP2951208A1 (en) 2015-12-09
JP6539585B2 (ja) 2019-07-03
CN105531289A (zh) 2016-04-27
KR102204127B1 (ko) 2021-01-20
CA2899960C (en) 2022-05-03
MX2015010023A (es) 2017-11-17
NZ711543A (en) 2020-08-28
CN105531289B (zh) 2019-02-22
EP2951208B1 (en) 2019-11-13
JP2016507521A (ja) 2016-03-10
EP2951208A4 (en) 2016-10-19
KR20150135250A (ko) 2015-12-02
CA2899960A1 (en) 2014-08-07
WO2014117220A1 (en) 2014-08-07
JP2019076102A (ja) 2019-05-23
US20180201681A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
US11725054B2 (en) Anti-CD83 antibodies and use thereof
US20240141053A1 (en) Antibodies against tl1a and uses thereof
TWI693233B (zh) Ｃｄ１２３結合劑及其用途
TW202118788A (zh) 包含血管舒緩素相關肽酶2抗原結合域之蛋白質及其用途
US20210101992A1 (en) Cd83 binding proteins and uses thereof
TW202144418A (zh) 唾液酸結合Ｉｇ樣凝集素結合的材料及方法
JP7744991B2 (ja) ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント
EP4304649A1 (en) Uses of cd79b antibodies for autoimmune therapeutic applications

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DENDROCYTE BIOTECH PTY LTD

Free format text: FORMER APPLICANT(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNIVERSITY OF QUEENSLAND; TRANSBIO LTD

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Free format text: FORMER APPLICANT(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNIVERSITY OF QUEENSLAND; TRANSBIO LTD

Owner name: THE UNIVERSITY OF QUEENSLAND

Free format text: FORMER APPLICANT(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNIVERSITY OF QUEENSLAND; TRANSBIO LTD

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: THE UNIVERSITY OF QUEENSLAND

Free format text: FORMER OWNER(S): THE UNIVERSITY OF QUEENSLAND; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; DENDROCYTE BIOTECH PTY LTD

Owner name: KIRA BIOTECH PTY LIMITED

Free format text: FORMER OWNER(S): THE UNIVERSITY OF QUEENSLAND; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; DENDROCYTE BIOTECH PTY LTD

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Free format text: FORMER OWNER(S): THE UNIVERSITY OF QUEENSLAND; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; DENDROCYTE BIOTECH PTY LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired